REG - OptiBiotix Health - Director Appointment

OptiBiotix HealthAnnouncement

10/09/2018 07:05

RNS Number : 1750A
OptiBiotix Health PLC
10 September 2018
 


OptiBiotix Health plc
("OptiBiotix")
 
Director Appointment
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol and diabetes, announces that, further to the previous announcement made on 6 August 2018 regarding the proposed appointment of Sean Christie as Non-Executive Director of the Company, the regulatory due diligence process has now been completed and the text below sets out the required disclosures.
 
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Michael Sean Christie (aged 60):
 



Current Appointments


Appointments in the last 5 years




ACCSYS Technologies Plc


Croda Enterprises Limited




Applied Graphene Materials Plc


Croda Europe Limited




Turner & Townsend Limited


Croda International Plc




 


Croda Investments Limited




 


Croda Investments No 2 Limited




 


Croda JDH Limited




 


Croda Overseas Holdings Limited




 


Croda Polymers International Limited




 


Croda World Traders Limited




 


Eminate Limited




 


Produce Investments Limited



 
 
For further information, please contact:
 



OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below














Cairn Financial Advisers LLP (NOMAD)


Tel: 020 7213 0880




Liam Murray / Jo Turner / Ludovico Lazzaretti








 
finnCap (Broker)


 
Tel: 020 7220 0500




Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)








Camille Gochez (Corporate Broking)


















Walbrook PR Ltd


Tel: 020 7933 8780 or optibiotix@walbrookpr.com




Anna Dunphy


Mob: 07876 741 001




Lianne Cawthorne


Mob: 07584 391 303








 
 
 
 
 
About OptiBiotix - www.optibiotix.com 
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 
 
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
 
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 
 
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUGURGBUPRGCM